Medical Device and In Vitro Diagnostics/Research Deal Statistics Quarterly, Q3 2009
Executive Summary
Medical device financing--primarily made up of late venture rounds--totaled just over $1 billion in Q3 2009, a 19% increase over the previous quarter. Acquisition dollars in the industry also surpassed $1 billion and included two $400 million-deals by Abbott. Most of the third quarter financing into in vitro diagnostics and research/analytical came from Qiagen's $628 million FOPO. And Agilent's $1.5 billion purchase of bioanalytical instrument maker Varian was the highest-value takeover.
You may also be interested in...
Covidien Gains BIS Anesthesia Monitoring Technology In Aspect Medical Buy
Covidien is adding brain monitoring technology to its lineup through the $210 million acquisition of Aspect Medical Systems, announced Sept. 28
With DxS, Qiagen Moves into Personalized Medicine
Qiagen has bought up DxS, a private UK-based provider of molecular tests including one for the mutant oncogene KRAS. Like the June 2009 deal by Labcorp. for Monogram Biosciences, it shows how IVD companies with very different business models are moving towards a common ground in personalized medicine and disease management.
Device Companies Look Far and Wide for New Capital
The global recession that struck last September drove many device investors into hiding. This left a barren financial landscape for device companies to subsist on. But some are finding the funds they need, and they're sharing their survival stories.